Detection method and combination for simultaneously detecting tumor specific gene mutation and methylation in one tube and application of detection method and combination
By combining capture probes and methylation-sensitive restriction enzymes, simultaneous detection of mutations and methylation states of multiple cancer genes is achieved, and the detection sensitivity and cost in the prior art is solved The problem has improved the efficiency and accuracy of early tumor screening.
Patent Information
- Application Number
- CN202411242027.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to detect mutations and methylation status of multiple cancer genes efficiently at the same time, and traditional methods have problems such as low detection sensitivity, high cost and complex operation, which limits the application of early tumor screening.
A one-tube method is used to combine capture probes and methylation-sensitive restriction enzymes to achieve simultaneous detection of tumor-specific gene mutations and methylation sites through specific target interval design and high-throughput sequencing.
The simultaneous detection of 55 cancer-driven genes is achieved, which improves detection sensitivity and efficiency, reduces cost and time, and can obtain high-quality high-throughput sequencing data in one experiment, which is suitable for early screening of multiple cancers.
Smart Images

Figure CN118932066A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of gene detection technology. Specifically, the present application provides a method and reagent for simultaneously detecting tumor-specific gene mutation and methylation in one tube. Background Art
[0002] Cancer is one of the main causes of death in humans. The main limiting factor affecting the clinical efficacy of cancer is the period of discovery and diagnosis. If it can be diagnosed and removed in the early stage (before cancer cells metastasize), cancer can be cured. Early cancer screening and diagnosis are important ways to reduce cancer mortality.
[0003] Early detection of cancer is very important for the treatment effect, but it is also a difficult problem that has been difficult to overcome in this field. At present, clinical early screening methods for tumors include imaging, endoscopy, and tumor markers. These detection technologies have defects such as invasiveness, discomfort during screening, and low detection sensitivity. Traditional methods have various limitations, and the clinic urgently needs some early screening technologies with high sensitivity / specificity and convenient operation.
[0004] In recent years, DNA molecular detection technology has developed rapidly, and tumor molecular marker detection has become a new field of tumor molecular diagnosis after imaging diagnosis and pathological diagnosis. Tumor DNA markers can be detected in body fluids and can reflect the existence and malignancy of tumors, which is of great significance for prognosis estimation and judgment of treatment effect.
[0005] As a new non-invasive detection technology, liquid biopsy has great application potential in early cancer screening. Tumor markers of liquid biopsy mainly include genome, epigenome, transcriptome, microbiome, proteome and metabolome. The characteristics of tumor markers at the ctDNA level include point mutations, fragmentation, copy number changes and methylation. Among them, DNA mutations and methylation occur in almost all tumors. Therefore, the combination of mutation and methylation co-detection technology can help the implementation of early screening technology for multiple cancers.
[0006] Bisulfite sequencing, a gold standard for methylation sequencing, is referred to as BS-seq. The detection principle is to treat the sample DNA with bisulfite, convert the unmethylated C base into U base, and after PCR amplification, convert the U base into T, and compare it with the unconverted sequence to determine whether the site has been methylated. This method has a high degradation rate for DNA, and cannot achieve the experimental purpose of co-detection of mutation and methylation in the same hybridization capture system, so there is no way to perform methylation detection and mutation detection at the same time.
[0007] The existing gene detection methods are mostly focused on detecting mutations and methylation status separately, and there are few reports on detecting multiple cancer gene mutations and methylation status simultaneously. The limitations of the detection range in clinical practice (mutation or methylation detection of several sites), the low content of ctDNA commonly used in liquid biopsies (mutation frequency is generally as low as 0.1-1%), and the high detection cost of Sanger sequencing technology multi-gene detection have greatly restricted its actual clinical application. Therefore, it is an urgent problem to establish a set of efficient, fast, sensitive, economical means that can simultaneously detect multiple cancer gene mutations and methylation status in one tube. Summary of the invention
[0008] In one aspect, the present application provides a method for simultaneously detecting tumor-specific gene mutations and methylation in one tube, the method comprising the following steps:
[0009] (1) Selecting tumor-specific mutant genes and tumor-specific methylated genes, selecting the mutation sites of tumor-specific mutant genes and the methylation sites of tumor-specific methylated genes, and selecting the mutation sites of tumor-specific mutant genes and the methylation sites of tumor-specific methylated genes and the regions extending 30-100 bp upstream and downstream thereof as the tumor-specific mutant gene target interval and the tumor-specific methylated gene target interval;
[0010] (2) synthesizing capture probes that are paired with corresponding target intervals, wherein the capture probes are composed of a probe binding sequence that is complementary to an adjacent capture probe in the same interval and a target-specific sequence that is complementary to a tumor-specific mutation gene target interval or a tumor-specific methylation gene target interval;
[0011] (3) extracting free DNA or genomic DNA from the sample to be tested, mixing it with exogenous DNA, performing end-filling repair, adding "A" and ligation, and obtaining a sample ligation product of the sample after purification;
[0012] (4) treating the sample ligation product with a methylation-sensitive restriction endonuclease, connecting the DNA fragment to the index adapter through PCR amplification, and obtaining the sample DNA methylation and mutation pre-library after purification;
[0013] (5) hybridizing the DNA methylation and mutation prelibrary prepared in step (4) using a capture probe to capture the methylated and mutant DNA sequences in the target region;
[0014] (6) performing PCR amplification on the DNA sequence of the capture target region to obtain an amplified product;
[0015] (7) purifying the amplified product in step (6), performing quality inspection before release, and obtaining a methylation and mutation library of the target region;
[0016] (8) performing high-throughput sequencing on the methylation and mutation libraries of the target region constructed in step (7) to obtain the sequence of the target fragment;
[0017] (9) Compare and analyze the sequence information of the obtained target fragment with the normal gene sequence to obtain the mutation and methylation information of the target fragment.
[0018] The interval described in the present application refers to a specific part of a specific gene being detected, such as the "H4C6 gene chr6: 26240658-26240991 position" shown in the Examples.
[0019] Furthermore, in step (1), methylation and mutation sites of cancer-related genes are selected based on literature and TCGA and COSMIC data.
[0020] Furthermore, the tumor-specific mutant gene is selected from one or more of NRAS, CTNNB1, PIK3CA, FBXW7, APC, EGFR, BRAF, CDKN2A, PTEN, FGFR2, HRAS, KRAS, AKT1, TP53, PPP2R1A, and GNAS.
[0021] Furthermore, the tumor-specific mutation gene target intervals are chr1:115256462-115256611, chr1:115258679-115258834, chr10:89692723-89693040, chr10:123279607-123279757, chr11:534208-534345, chr12:25378488-25378637, chr12:25380204-25380355, chr12:25398219-25398366, chr14: 105246490-105246643, chr17:7572893-7573080, chr17:7573907-7574089, chr17:7576783-7577228, chr17:7577440-7577667, c hr17:7578099-7578633, chr17:7579220-7579944, chr19:52715900-52716054, chr20:57484357-57484503, chr3:41266034-4126 6205, chr3:178916784-178916941, chr3:178921480-178921626, chr3:178936016-178936175, chr3:178951998-178952156, chr4 :153247221-153247419、chr4:153249298-153249453、chr4:153251828-153251987、chr5:112175138-112175286、chr5:11217557 8-112175730, chr7:5571691-5571899, chr7:55232932-55233170, chr7:55241573-55241776, chr7:55242374-55242553, chr7:55 248945-55249211, chr7:55259371-55259607, chr7:55268840-55269073, chr7:140453072-140453231, chr9:21971056-21971281.
[0022] Furthermore, the tumor-specific methylation genes are SHOX2, PTGER4, H4C6, RASSF1A, Septin9, RNF180, SDC2, PAX1, ZNF671, BMPR1A, PLAC8, EVX1, GNB4, SIX6, PCDHGB7, DAPK1, GSTP1, HIC1, RUNX3, VHL, WT1, BMP3, NDRG4, BCAT1, Twist1, JAM3, TFPI2, CDO1, LYPD5, HOXA9, BNC1, PENK, SFRP1, PCDH8, ADAM23, CHST11, C2orf88, MCF2L, CAMK2N1, and TACSTD2.
[0023] The tumor-specific methylation gene target intervals are chr1:20810296-20810635, chr1:25255411-25255652, chr1:59042517-59043026, chr10:88515764-88516078, chr10:88516143-88516235, chr11:32354800-32355439, chr11:67350903-67351488, chr11:133939397-133939638, chr12:25055729-25056569, chr12:104850537-1048 50822, chr13:53421948-53422217, chr13:53422689-53422828, chr13:11 3623367-113623449, chr13:113623511-113623603, chr14:60976415-609 76602, chr15:83952782-83953090, chr16:58497189-58497988, chr17:19 57373-1957754, chr17:75368649-75370546, chr19:44302727-44303241, c hr19:58238546-58239068, chr2:191044925-191045141, chr2:207308920 -207309240、chr20:21686160-21686478、chr20:21686644-21687729、chr 3:10183433-10183998, chr3:50377764-50378580, chr3:157821193-1578 21570, chr3:179168719-179168984, chr3:179169053-179169633, chr4:81 951952-81952848, chr4:84030745-84031349, chr5:40680835-40682071, chr5:63461409-63461789、chr5:63461875-63462146、chr5:115151476-11 5152553, chr5:140797123-140797741, chr6:26240658-26240991, chr7:1 9147401-19147925、chr7:27204944-27205261、chr7:27282047-27282879、chr7:27282942-27283176, chr7:93519247-93520492, chr8:41166830-41167127, chr8:411684 04-41168548, chr8:57358291-57359351, chr8:97505708-97507647, chr9:90113255-90113681. ,
[0024] Furthermore, the variant gene types of the mutation site include point mutation and insertion-deletion mutation.
[0025] Furthermore, the methylation site includes a site recognized by a methylation-sensitive restriction endonuclease.
[0026] Furthermore, the methylation-sensitive restriction endonuclease is selected from HpaI, HpaII, HhaI, AciI and a combination thereof.
[0027] Furthermore, the 5' end of the capture probe is a first probe binding sequence, which is complementary to the 3' end of another capture probe 1, and the 3' end of the capture probe is a second probe binding sequence, which is complementary to the 5' end of another capture probe 2; the lengths of the first and second probe binding sequences are 8-30nt, the length of the target-specific sequence is 20-80nt, and the 5' end of the capture probe is modified with biotin; the other capture probe 1 and the other capture probe 2 are not the same probe.
[0028] Furthermore, in step (3), genomic DNA is extracted from cell lines, tumor tissues or exfoliated cells, or free DNA is extracted from plasma, urine, pleural effusion or ascites.
[0029] Furthermore, the sample ligation product in step (3) includes the entire sequence of the sample DNA and the added exogenous DNA.
[0030] Furthermore, the exogenous DNA is Lambda DNA, which is used to monitor the digestion efficiency of a methylation-sensitive restriction endonuclease.
[0031] Furthermore, in step (5), 1-10 sample pre-libraries are hybridized simultaneously.
[0032] Furthermore, the library quality inspection requires that the library concentration is greater than or equal to 1.5 ng / μL and the fragments are evenly distributed between 200 and 1000 bp.
[0033] The above methods can be used for diagnostic or non-diagnostic purposes. Non-diagnostic purposes include but are not limited to scientific research data statistics, etc.
[0034] On the other hand, the present application provides a tube of reagent for simultaneously detecting tumor-specific gene mutations and methylation, wherein the reagent includes a capture probe, which is composed of a probe binding sequence that is complementarily paired with an adjacent capture probe in the same interval and a target-specific sequence that is complementarily paired with a tumor-specific mutation gene target interval or a tumor-specific methylation gene target interval.
[0035] Furthermore, the tumor-specific mutant genes are NRAS, CTNNB1, PIK3CA, FBXW7, APC, EGFR, BRAF, CDKN2A, PTEN, FGFR2, HRAS, KRAS, AKT1, TP53, PPP2R1A, and GNAS.
[0036] Furthermore, the tumor-specific mutation gene target intervals are chr1:115256462-115256611, chr1:115258679-115258834, chr10:89692723-89693040, chr10:123279607-123279757, chr11:534208-534345, chr12:25378488-25378637, chr12:25380204-25380355, chr12:25398219-25398366, chr14: 105246490-105246643, chr17:7572893-7573080, chr17:7573907-7574089, chr17:7576783-7577228, chr17:7577440-7577667, c hr17:7578099-7578633, chr17:7579220-7579944, chr19:52715900-52716054, chr20:57484357-57484503, chr3:41266034-4126 6205, chr3:178916784-178916941, chr3:178921480-178921626, chr3:178936016-178936175, chr3:178951998-178952156, chr4 :153247221-153247419、chr4:153249298-153249453、chr4:153251828-153251987、chr5:112175138-112175286、chr5:11217557 8-112175730, chr7:5571691-5571899, chr7:55232932-55233170, chr7:55241573-55241776, chr7:55242374-55242553, chr7:55 248945-55249211, chr7:55259371-55259607, chr7:55268840-55269073, chr7:140453072-140453231, chr9:21971056-21971281.
[0037] Furthermore, the tumor-specific methylation genes are SHOX2, PTGER4, H4C6, RASSF1A, Septin9, RNF180, SDC2, PAX1, ZNF671, BMPR1A, PLAC8, EVX1, GNB4, SIX6, PCDHGB7, DAPK1, GSTP1, HIC1, RUNX3, VHL, WT1, BMP3, NDRG4, BCAT1, Twist1, JAM3, TFPI2, CDO1, LYPD5, HOXA9, BNC1, PENK, SFRP1, PCDH8, ADAM23, CHST11, C2orf88, MCF2L, CAMK2N1, and TACSTD2.
[0038] The tumor-specific methylation gene target intervals are chr1:20810296-20810635, chr1:25255411-25255652, chr1:59042517-59043026, chr10:88515764-88516078, chr10:88516143-88516235, chr11:32354800-32355439, chr11:67350903-67351488, chr11:133939397-133939638, chr12:25055729-25056569, chr12:104850537-1048 50822, chr13:53421948-53422217, chr13:53422689-53422828, chr13:11 3623367-113623449, chr13:113623511-113623603, chr14:60976415-609 76602, chr15:83952782-83953090, chr16:58497189-58497988, chr17:19 57373-1957754, chr17:75368649-75370546, chr19:44302727-44303241, c hr19:58238546-58239068, chr2:191044925-191045141, chr2:207308920 -207309240、chr20:21686160-21686478、chr20:21686644-21687729、chr 3:10183433-10183998, chr3:50377764-50378580, chr3:157821193-1578 21570, chr3:179168719-179168984, chr3:179169053-179169633, chr4:81 951952-81952848, chr4:84030745-84031349, chr5:40680835-40682071, chr5:63461409-63461789、chr5:63461875-63462146、chr5:115151476-11 5152553, chr5:140797123-140797741, chr6:26240658-26240991, chr7:1 9147401-19147925、chr7:27204944-27205261、chr7:27282047-27282879、chr7:27282942-27283176, chr7:93519247-93520492, chr8:41166830-41167127, chr8:411684 04-41168548, chr8:57358291-57359351, chr8:97505708-97507647, chr9:90113255-90113681. ,
[0039] Furthermore, the 5' end of the capture probe is a first probe binding sequence, which is complementary to the 3' end of another capture probe 1, and the 3' end of the capture probe is a second probe binding sequence, which is complementary to the 5' end of another capture probe 2; the lengths of the first and second probe binding sequences are 8-30nt, the length of the target-specific sequence is 20-80nt, and the 5' end of the capture probe is modified with biotin; the other capture probe 1 and the other capture probe 2 are not the same probe.
[0040] Furthermore, the kit also includes a methylation-sensitive restriction endonuclease.
[0041] Furthermore, the kit also includes exogenous DNA.
[0042] Furthermore, the exogenous DNA is Lambda DNA, which is used to monitor the enzyme cutting efficiency of a methylation-sensitive restriction endonuclease.
[0043] Furthermore, the methylation-sensitive restriction endonuclease is selected from HpaI, HpaII, HhaI, AciI and a combination thereof.
[0044] On the other hand, the present application provides the use of the above reagents in the preparation of diagnostic reagents for tumor mutation and methylation status.
[0045] Compared with the prior art, the beneficial effects of the present invention include:
[0046] (1) The present invention can accurately and simultaneously detect point mutations, insertion / deletion variations, and methylation status of 55 genes (including cancer driver genes and tumor suppressor genes). Existing methods mostly detect mutations and methylation status separately, but fail to solve the problem of simultaneously detecting mutations and methylation status of multiple cancer genes. The present invention can simultaneously detect mutations and methylation status of multiple cancer genes through one tube.
[0047] (2) The present invention conducts targeted detection based on the tumor-related gene hotspots designed above, including point mutations, insertion and deletion variations, and methylation status of tumor-specific genes related to various cancers such as lung cancer, colorectal cancer, esophageal cancer, liver cancer, gastric cancer, bladder cancer, cervical cancer, breast cancer, ovarian cancer, etc. Through a single test, multiple cancer gene mutation and methylation status information can be obtained, providing guidance and suggestions for early detection of tumors.
[0048] (3) The enzyme digestion efficiency of the present invention for free DNA is greater than 99%, and the enzyme digestion recovery rate is greater than 95%; the ligation enzyme digestion recovery rate is greater than 50%, which is similar to the simple ligation recovery rate and has no effect on the number of mutant fragments of related genes.
[0049] (4) The hybridization capture time of the present invention only takes 2 hours, and up to 10 samples can be hybridized in one capture, saving cost and time.
[0050] (5) The present invention can obtain high-quality high-throughput sequencing data (Q30>90%), and each sample only requires 0.5G of data.
[0051] (6) The probe of the present invention can achieve a matching rate (the ratio of data matching to the genome) of 98%, a capture efficiency (the ratio of the number of target region sequences to the total sequence measured) of greater than 40%, and a uniformity (0.2×average coverage percentage) of greater than 90%. Parameters such as coverage, capture efficiency, and uniformity are directly related to the design of the target. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 Schematic diagram of the experimental process and operation time for methylation and mutation targeted detection;
[0053] Figure 2 This is a schematic diagram of the ligation and digestion recovery results of free DNA in Example 2;
[0054] Figure 3 Schematic diagram of the quality effect of samples in Examples 3, 4, 5, and 6;
[0055] Figure 4 This is a schematic diagram of the mutation detection results of the mutation standard in Example 3;
[0056] Figure 5 This is a schematic diagram of the methylation detection results of the methylation standard in Example 4;
[0057] Figure 6 This is a schematic diagram of the detection results of some methylation sites of lung cancer samples in Example 5;
[0058] Figure 7 This is a schematic diagram of the detection results of some methylation sites in liver cancer samples in Example 6. DETAILED DESCRIPTION
[0059] The basic steps are as follows: Figure 1 shown.
[0060] Testing steps:
[0061] 1. Select the methylation and mutation sites of cancer-related genes in Table 1 through the database and extend their upstream and downstream by 30-100bp as the target interval.
[0062] 2. Synthesize capture probes that are paired with the target intervals, wherein the probes include a probe binding sequence that is complementary to another probe and a target specific sequence that is complementary to the nucleic acid target sequence. The length of the probe binding sequence is 8-30 nt, the length of the target specific sequence is 20-80 nt, and the 5' end is biotin-modified.
[0063] 3. Sample DNA extraction and mixing with Lambda DNA
[0064] Use plasma free DNA or exfoliated cell DNA extraction kit to extract sample DNA, and refer to the extraction kit steps. Genomic DNA samples need to be fragmented into 180-220bp DNA fragments, and free DNA is directly mixed with a certain proportion of Lambda DNA (when the sample input amount is 10ng≤n<40ng, Lambda DNA is mixed with 0.165pg; when the sample input amount is <10ng, Lambda DNA is mixed with 0.05pg).
[0065] 4. Use End Repair & A-Tailing Enzyme to fill in the ends, add "A" and connect through T4 DNA Ligase, connect the DNA fragments to the universal adapter (the relevant reagents are from NadPrep DNA Library Preparation Kit (for Illumina) E96), and after purification, obtain 17-34μL of sample connection product.
[0066] 5. Methylation-sensitive restriction endonuclease HhaI for digestion and library construction
[0067] The sample ligation product was treated with a methylation-sensitive restriction endonuclease, and the DNA fragment was connected to the index adapter through PCR amplification. After purification, the sample DNA methylation and mutation pre-library was obtained;
[0068] 5.1 Prepare the MSRE reaction solution according to the table below, vortex mix the prepared reaction system, centrifuge briefly, and place on ice for later use.
[0069] Note: All reagents must be melted and mixed thoroughly before use. The melted reagents should be placed on an ice box for later use. After use, please return them to storage conditions immediately.
[0070]
[0071] 5.2 Add 3 μL of MSRE reaction solution to the sample tube in step 4, vortex to mix, centrifuge briefly, and run the following program on the PCR instrument (the temperature of the hot cover is set to 90°C):
[0072] step Temperature ℃ Time min 1 37℃ 60min 2 80℃ 20min 3 4℃ hold
[0073] 5.3 Purification after MSRE reaction
[0074] After the MSRE reaction is completed, use AMPure beads for purification. Note that the AMPure beads must be equilibrated at room temperature for at least 30 minutes before use.
[0075] a. Purify AMPure beads and equilibrate them at room temperature for at least 30 minutes;
[0076] b. Add 30 μL of Nuclease Free Water to 20 μL of sample and vortex to mix;
[0077] c. Add 90 μL AMPure beads to the reaction system and vortex to mix evenly;
[0078] d. Let the mixture stand at room temperature for 5-10 minutes, then place it on a magnetic rack and let it stand for about 3-5 minutes. When the magnetic beads are completely separated from the solution, carefully remove the supernatant.
[0079] e. Wash the beads with 200 μL of 80% ethanol. Repeat this process for a total of 2 washes.
[0080] f. Air dry on the magnetic rack until the beads are dry. [Note: Do not over dry or over wet]
[0081] g. Use 20 μL of Nuclease Free Water to resuspend the dried magnetic beads and let stand at room temperature for about 5 minutes. Place the centrifuge tube on the magnetic rack, and when the supernatant is clear, take the supernatant to a new PCR tube and place it on ice for later use.
[0082] 5.4 PCR amplification to connect DNA fragments to index adapters
[0083] a. Prepare the amplification reaction solution according to the table below, vortex mix the prepared reaction system, centrifuge briefly, and place on ice for later use.
[0084] Note: All reagents must be melted and mixed thoroughly before use. The melted reagents should be placed on an ice box for later use. After use, please return them to storage conditions immediately.
[0085]
[0086] b. Add 5 μL of Universal UDI-Index PrimerMix, be sure to record the index corresponding to each sample, then add 25μL of amplification reaction solution to the reaction tube, vortex to mix, briefly centrifuge, and run the following program on the PCR instrument (heat cover set to 105℃):
[0087]
[0088] 5.5 Purification of pre-library
[0089] After the amplification reaction is completed, perform purification according to the following steps. Purify the AMPure beads. Note that the purified AMPure beads should be equilibrated at room temperature for at least 30 minutes before use.
[0090] a. Add 50 μL of AMPure beads to the PCR tube containing the amplification product from step 5.4.b and mix well;
[0091] b. Follow 5.4.dg;
[0092] 6. Quality control of pre-library
[0093] The pre-library was subjected to concentration quality control using HS dsDNA reagent and Qubit 4.0 instrument. To meet the downstream pooling requirements, the Qubit concentration was ≥ 30 ng / μL.
[0094] 7. Pooling of pre-library
[0095] When pooling, follow the rule of 500 ng / sample and mix 10 samples.
[0096] 8. Concentration after pre-library pooling.
[0097] 8.1 Add AMPure beads (1.8 times the total volume after library pooling) and vortex to mix.
[0098] 8.2 Follow the steps in 5.4.df.
[0099] 8.3 Add 19 μL Nuclease Free Water to the dried centrifuge tube, vortex to mix, and incubate at room temperature for 5 minutes.
[0100] 8.4 Centrifuge the tube briefly and place it on a magnetic rack for 2-5 minutes until the liquid is completely clear. Use a pipette to transfer all the supernatant to a new 0.2 mL PCR tube.
[0101] 9. Library Hybridization
[0102] 9.1 System Configuration
[0103] Prepare the library hybridization reaction solution according to the following table:
[0104] Note: All reagents must be melted and mixed thoroughly before use. The melted reagents should be placed on an ice box for later use. After use, please return them to storage conditions immediately.
[0105] Reagents Addition volume μL / hybridization library Custom panel 2(Single plus) Human Cot DNA 2 μCaler NanoBlockers(for Illumina) 2 μHyb#1 30 μHyb#2 6 total 42
[0106] The prepared reaction system was vortexed to mix, centrifuged briefly, and placed on ice for later use.
[0107] 9.2 Library hybridization reaction
[0108] Add 40 μL of hybridization reaction solution to the product of 8.4, and then add 2 μL of Custom panel probe separately, vortex to mix, centrifuge briefly, and run the following program on the PCR instrument (heat cover set to 105°C):
[0109] step Temperature ℃ Time min 1 98℃ 2min 2 60℃ 120min 3 60℃ hold
[0110] 10. Library capture and elution
[0111] 10.1 Magnetic Bead Cleaning
[0112] a. Vortex the Streptavidin Beads that have been equilibrated at room temperature for at least 30 minutes for 15 seconds to ensure complete mixing;
[0113] b. Take n×25μL Streptavidin Beads and mix and wash in a 0.2mL centrifuge tube (n is the total number of capture reactions, and n≤5; when n>5, it must be divided into multiple tubes for mixing and washing).
[0114] c. Place the Streptavidin Beads on a magnetic rack and let it stand for about 2 minutes. When the liquid is completely clear, use a pipette to discard the supernatant.
[0115] d. Remove the centrifuge tube from the magnetic stand, add 150 μL preheated Wash Buffer A Pro, and mix gently by pipetting for more than 10 times.
[0116] e. Place the centrifuge tube on the magnetic rack and let it stand for about 2 minutes. When the liquid is completely clear, use a pipette to discard the supernatant.
[0117] f. Repeat steps d and e once (Note: Wash Buffer A Pro must be returned to 50-60°C for heating).
[0118] g. Centrifuge the tube briefly and place it on a magnetic rack for 10 seconds. Use a 10μL pipette tip to discard all the WashBuffer A Pro at the bottom of the tube.
[0119] h. Take n×9μLμHyb#1 to resuspend Streptavidin Beads and gently blow and mix for more than 10 times.
[0120] 10.2 Magnetic Bead Capture and Elution
[0121] a. After the hybridization reaction, enter the capture phase and maintain the PCR instrument running state.
[0122] b. Keep the PCR tube in the PCR instrument, take 8 μL of resuspended Streptavidin Beads and immediately add it to each hybridization reaction solution, and mix it by gently pipetting for more than 10 times.
[0123] c. Incubate at 60°C for 10 min.
[0124] d. After the incubation is completed, remove the PCR tube from the PCR instrument and place it on a magnetic rack for 2 minutes. When the liquid is completely clear, use a pipette to discard the supernatant (try to remove the supernatant as much as possible).
[0125] e. Remove the PCR tube from the magnetic rack, add 150 μL preheated Wash Bufer APro, and mix by gently pipetting for more than 10 times (avoid creating bubbles).
[0126] f. Place the PCR tube on a magnetic rack and let it stand for 2 minutes. When the liquid is completely clear, use a pipette to discard the supernatant (try to remove as much of the supernatant as possible).
[0127] g. Remove the PCR tube from the magnetic rack, add 100 μL preheated Wash Buffer A Pro, mix by gently pipetting for more than 10 times, and transfer the reaction solution to a new PCR tube (Note: Try to avoid generating bubbles in this step, as bubbles contacting the tube cap may reduce the on-target rate).
[0128] h. Place the PCR tube into the PCR instrument and incubate at 60°C for 3 min.
[0129] i. After the incubation is completed, remove the PCR tube from the PCR instrument and place it on a magnetic rack for 2 minutes. When the liquid is completely clear, use a pipette to discard the supernatant (try to remove the supernatant as much as possible).
[0130] j. Add 150 μL of room temperature Wash Buffer B to the PCR tube and mix by gently pipetting for more than 10 times.
[0131] k. Place the PCR tube on a magnetic rack and let it stand for 2 minutes. When the liquid is completely clear, use a pipette to discard the supernatant.
[0132] l. Centrifuge the PCR tube briefly and place it on a magnetic rack. Use a 10μL pipette to remove a small amount of residual liquid, being careful not to suck up the magnetic beads.
[0133] m. Add 22.5μL Nuclease Free Water, gently pipette for more than 10 times to resuspend the magnetic beads and transfer all the resuspended magnetic beads to a new PCR tube. (Note: Transferring the tube here can reduce nonspecific capture and increase the on-target rate).
[0134] 11. PCR Amplification and Purification of Hybrid Capture Library
[0135] 11.1 Configuration of hybrid capture library PCR reaction system
[0136] Prepare the hybridization capture library PCR reaction solution according to the following table:
[0137] Note: All reagents must be melted and mixed thoroughly before use. The melted reagents should be placed on an ice box for later use. After use, please return them to storage conditions immediately.
[0138]
[0139]
[0140] The prepared reaction system was vortexed to mix, centrifuged briefly, and placed on ice for later use.
[0141] 11.2 Hybridization capture library PCR reaction
[0142] Add the hybridization capture library PCR reaction solution to the product of 11.1.m, vortex to mix, and run the following program on the PCR instrument (heat cover set to 105℃):
[0143]
[0144] 11.3 After the hybridization capture library PCR reaction, the PCR amplification product is purified using AMPure beads to obtain the captured sample library.
[0145] 12. Hybridization capture library quality inspection
[0146] 12.1 Concentration Quality Control
[0147] The hybridization capture library was subjected to concentration quality control using HS dsDNA reagent and Qubit 4.0 instrument. To meet the downstream sequencing requirements, the concentration of the hybridization capture library was ≥1.5 ng / μL.
[0148] 12.2 Fragment Quality Control
[0149] The library fragment size was determined using Qsep-1 / Labchip GX Touch (Caliper), and the average fragment length was in the range of 200-1000 bp.
[0150] 13. Sequencing
[0151] The present invention uses a second-generation sequencing platform well known to those skilled in the art to perform high-throughput sequencing, and the captured sequences are sequenced on an Illumina sequencing platform using a sequencing-by-synthesis method.
[0152] 14. Data Processing and Analysis
[0153] 14.1 Analyze the variant data and filter the results using fastp. The filtering conditions are as follows: retain variants that meet the following filtering conditions: base quality ≥ 20, sequence alignment quality ≥ 5, and chain preference < 90%.
[0154] 14.2bwa is aligned to the reference genome.
[0155] 14.3 Filter unmapped reads, secondary aligned reads, or multiple aligned reads.
[0156] 14.4 Remove PCR duplicates and analyze methylation and mutation levels.
[0157] The present invention is further described below in conjunction with specific embodiments.
[0158] Example 1 Screening of human tumor-related methylation and mutation sites and probe design method
[0159] In this study, we first used GEO to select pan-cancer (here pan-cancer is defined as all cancer types in TCGA pan-cancer data, including urothelial carcinoma, breast cancer, cervical cancer, bile duct cancer, colon cancer, esophageal cancer, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, endometrial cancer, etc.) sample data, screened abnormal methylation-differentially expressed genes in tumors, used Metascape for functional enrichment analysis, and used Cytoscape for important module gene screening. Then, we used the UALCAN database to verify abnormal methylation-differentially expressed genes, and further combined R language with TCGA cancer data to screen methylation target genes that affect the prognosis of specific cancers, and performed survival and correlation analysis of methylation CpG sites. Finally, GSEA enrichment analysis was performed on the selected key methylation target genes, as well as correlation analysis between methylation target genes and clinical pathological characteristics. Combined with the methylation gene sites screened in the literature and TCGA data, a methylation detection panel was finally combined.
[0160] Combined with articles published in the field of cancer mutation spectrum and screening in recent years and sequencing data in the COSMIC database, mutant genes and mutation sites with a high correlation with cancer occurrence were screened out. Using liquid biopsy, ctDNA, somatic mutation, tumor screening, cancer, early cancer screening, etc. as keywords, literature search was conducted in the PubMed database. According to the search results, mutant genes and sites related to cancer were sorted out. In the COSMIC database, select Cancer Browser, then select a certain cancer in Tissue selection, Histology selection, Sub-histology selection, and sort out the sequencing data of all samples of this cancer in the database. Screen among the top 20 genes with mutation frequencies, and select mutation sites with more than 5 samples. Combine the gene sites screened out in the literature and COSMIC data, and finally combine them into a mutation detection panel.
[0161] The methylation detection panel and the mutation detection panel were combined to obtain the panel interval for co-detection of methylation and mutation as shown in Table 1.
[0162] Table 1 Selected cancer-related gene capture regions Notes: Chr: chromosome; Start: interval starting position; End: interval ending position.
[0163]
[0164]
[0165]
[0166] Capture probes are designed for the intervals in Table 1. The probe sequence includes a probe binding sequence complementary to another probe and a target specific sequence complementary to the nucleic acid target sequence. The length of the probe binding sequence is 8-30 nt, the length of the target specific sequence is 20-80 nt, and the 5' end is biotin-modified. Some probe sequences are shown in Table 2.
[0167] Table 2 Some examples of probe sequences
[0168]
[0169]
[0170] Example 2 Effect of methylated restriction endonucleases on detection of mutant fragments
[0171] The sample in this example is a plasma sample from a healthy person, and the effect of methylation restriction endonuclease on the detection of mutant fragments was evaluated. The specific operation is as follows:
[0172] (1) cfDNA was extracted according to the above method. After extraction, the concentration was determined to be 0.91 ng / μL using Qubit 4.0. 5 μL cfDNA sample was taken for real-time fluorescence quantitative PCR detection of the actin gene and recorded as CT1;
[0173] (2) Take 10 ng (10.99 μL) of cfDNA for end repair, adapter ligation, and adapter ligation followed by purification. After ligation and purification, use 35 μL of nuclease-free water for elution, and take 5 μL of the eluate for real-time fluorescence quantitative PCR detection of the actin gene, which is recorded as CT2;
[0174] (3) Take 17 μL from (2) to perform MSRE reaction; after MSRE reaction and MSRE reaction purification, use 20 μL nuclease-free water to elute, take 5 μL of the eluate to perform real-time fluorescence quantitative PCR detection of the actin gene, and record it as CT3;
[0175] (4) After the real-time fluorescence quantitative PCR detection of the actin gene is completed, the ligation recovery efficiency, the enzyme digestion recovery efficiency and the ligation enzyme digestion recovery efficiency are calculated according to the difference of the above CT values. The specific calculation formula is as follows:
[0176] a) Connection recovery efficiency = 1 / 2^(CT2-CT1)*35 / 10.99
[0177] b) Enzyme digestion recovery efficiency = 1 / 2^(CT3-CT2)*17 / 20
[0178] c) Ligation recovery efficiency = ligation recovery efficiency * enzyme recovery efficiency
[0179] The test results are shown in Table 3 and Figure 2 The results showed that the enzyme digestion efficiency of this mutation / methylation co-detection method for free DNA was greater than 99%, and the enzyme digestion recovery rate was greater than 95%. The ligation enzyme digestion recovery rate was greater than 50%, which was similar to the simple ligation recovery rate, and had no effect on the number of mutation fragments of related genes.
[0180] Table 3 Test results of Example 2
[0181]
[0182] The quality of the samples in the following Examples 3, 4, 5, and 6 is as follows: Figure 3 shown.
[0183] Example 3 Accuracy of gene mutation detection
[0184] The sample in this example is a gDNA mutation standard from Horizon Discovery, with the product catalog number HD827. The standard contains multiple mutation sites verified by digital PCR.
[0185] First, the gDNA mutation standard was physically sheared into fragments of 200-300 bp in size, and then 40 ng was taken and invested to complete end repair and A addition, adapter ligation, MSRE reaction, sublibrary enrichment, sublibrary pooling, hybridization capture of target sequences, cleaning and enrichment purification, library quality inspection, sequencing and data processing and analysis according to the above steps 3-14.
[0186] According to the sequencing results, the mutation frequency of the mutation site was obtained. The test results are shown in Table 4 and Figure 4 The results showed that the mutation frequency of the mutation site obtained by using the mutation / methylation co-detection method to detect the mutation standard was basically close to the theoretical value of the standard. This shows that this method has a high accuracy in detecting related gene mutations.
[0187] Table 4 Test results of Example 3
[0188]
[0189] Note: Cosmic ID represents the gene written in the Cosmic database, Ref represents the normal type, Alt represents the type after gene mutation, DEL represents deletion, and SNP represents single base mutation.
[0190] Example 4 Accuracy of methylation detection
[0191] The samples in this example are gDNA negative methylation standards and positive methylation standards from Zymo Research, and the methylation sites in the standards are verified by NGS.
[0192] First, the gDNA methylation standard was physically sheared into fragments of 200-300 bp in size, and then 40 ng was taken and invested to complete end repair and A addition, adapter ligation, MSRE reaction, sublibrary enrichment, sublibrary pooling, hybridization capture of target sequences, cleaning and enrichment purification, library quality inspection, sequencing and data processing and analysis according to the above steps 3-14.
[0193] According to the sequencing results, the methylation level was obtained. The test results are shown in Table 5 and Appendix Figure 5 The results showed that the detection value of the methylation standard was close to the theoretical value when the mutation / methylation co-detection method was used. This shows that this method has a high accuracy in detecting the methylation of related genes.
[0194] Table 5
[0195]
[0196] Example 5 Actual lung cancer sample detection
[0197] The samples in this example were derived from stage IV lung cancer patients with invasive adenocarcinoma of the right upper lung, and the sample source was plasma separated from the peripheral blood of the lung cancer patients before surgery.
[0198] First, free DNA was extracted from the plasma sample with a concentration of 0.7 ng / μL. Then 26 ng was taken and invested to complete end repair and A addition, adapter ligation, MSRE reaction, sublibrary enrichment, sublibrary pooling, hybridization capture of target sequences, cleaning and enrichment purification, library quality inspection, sequencing and data processing and analysis according to the above steps 3-14.
[0199] According to the sequencing results, the methylation and mutation results were obtained. The test results are shown in Table 6 and Figure 6 As shown in Table 6, the KRAS gene in this sample had a G35T mutation with a mutation frequency of 2.91%. Figure 5 As shown, the level of lung cancer-related methylation sites in this sample is significantly different from that in normal people.
[0200] Table 6 Actual sample test 1 results
[0201]
[0202] Example 6 Actual liver cancer sample detection
[0203] The samples in this example are from patients with hepatocellular carcinoma stage IV, and the sample source is plasma separated from the peripheral blood of the patients with liver cancer before surgery.
[0204] First, free DNA was extracted from the plasma sample with a concentration of 3.0 ng / μL. Then 40 ng was taken and invested to complete end repair and A addition, adapter ligation, MSRE reaction, sublibrary enrichment, sublibrary pooling, hybridization capture of target sequences, cleaning and enrichment purification, library quality inspection, sequencing and data processing and analysis according to the above steps 3-14.
[0205] According to the sequencing results, the methylation and mutation results were obtained. The test results are shown in Table 7 and Figure 7 As shown in Table 7, the TP53 gene of this sample has a G422A mutation with a mutation frequency of 1.69%. Figure 6 As shown, the level of liver cancer-related methylation sites in this sample was significantly different from that in normal people.
[0206] Table 7 Actual sample test 2 results
[0207]
[0208] The above results show that the detection method provided by the present invention has high sensitivity and wide coverage. It can detect methylation and mutation of 55 tumor-related genes at the same time. The embodiments are only several embodiments of the present invention, and their descriptions are more specific, but they cannot be understood as limiting the scope of the patent of the present invention. Therefore, the scope of protection of the patent of the present invention shall be subject to the attached claims.
Claims
1. A method for simultaneously detecting tumor-specific gene mutation and methylation in one tube, characterized in that: The method comprises the following steps: (1) Selecting tumor-specific mutant genes and tumor-specific methylated genes, selecting the mutation sites of tumor-specific mutant genes and the methylation sites of tumor-specific methylated genes, and selecting the mutation sites of tumor-specific mutant genes and the methylation sites of tumor-specific methylated genes and the regions extending 30-100 bp upstream and downstream thereof as the tumor-specific mutant gene target interval and the tumor-specific methylated gene target interval; (2) synthesizing capture probes that are paired with corresponding target intervals, wherein the capture probes are composed of a probe binding sequence that is complementary to an adjacent capture probe in the same interval and a target-specific sequence that is complementary to a tumor-specific mutation gene target interval or a tumor-specific methylation gene target interval; (3) extracting free DNA or genomic DNA from the sample to be tested, mixing it with exogenous DNA, performing end-filling repair, adding "A" and ligation, and obtaining a sample ligation product of the sample after purification; (4) treating the sample ligation product with a methylation-sensitive restriction endonuclease, connecting the DNA fragment to the index adapter through PCR amplification, and obtaining the sample DNA methylation and mutation pre-library after purification; (5) hybridizing the DNA methylation and mutation prelibrary prepared in step (4) using a capture probe to capture the methylated and mutant DNA sequences in the target region; (6) performing PCR amplification on the DNA sequence of the capture target region to obtain an amplified product; (7) purifying the amplified product in step (6), performing quality inspection before release, and obtaining a methylation and mutation library of the target region; (8) performing high-throughput sequencing on the methylation and mutation libraries of the target region constructed in step (7) to obtain the sequence of the target fragment; (9) comparing the obtained sequence information of the target fragment with the normal gene sequence to obtain mutation and methylation information of the target fragment; The methods are for non-diagnostic use.
2. According to the method of claim 1, in step (1), methylation and mutation sites of cancer-related genes are selected in combination with literature and TCGA and COSMIC data.
3. According to the method of claim 1, the tumor-specific mutant genes are NRAS, CTNNB1, PIK3CA, FBXW7, APC, EGFR, BRAF, CDKN2A, PTEN, FGFR2, HRAS, KRAS, AKT1, TP53, PPP2R1A, and GNAS.
4. The method according to claim 3, wherein the tumor-specific mutation gene target intervals are chr1:115256462-115256611, chr1:115258679-115258834, chr10:89692723-89693040, chr10:123279607-123279757, chr11:534208-534345, chr12:25378488-25378637, chr12:25380204-25380355, chr12:25398219-2539836 6. chr14:105246490-105246643, chr17:7572893-7573080, chr17:7573907-7574089, chr17:7576783-7577228, chr17:7577440-75 77667, chr17:7578099-7578633, chr17:7579220-7579944, chr19:52715900-52716054, chr20:57484357-57484503, chr3:41266034 -41266205、chr3:178916784-178916941、chr3:178921480-178921626、chr3:178936016-178936175、chr3:178951998-178952156、 chr4:153247221-153247419, chr4:153249298-153249453, chr4:153251828-153251987, chr5:112175138-112175286, chr5:112175 578-112175730, chr7:5571691-5571899, chr7:55232932-55233170, chr7:55241573-55241776, chr7:55242374-55242553, chr7:5 5248945-55249211, chr7:55259371-55259607, chr7:55268840-55269073, chr7:140453072-140453231, chr9:21971056-21971281.
5. The method according to claim 1, wherein the tumor-specific methylation gene is SHOX2, PTGER4, H4C6, RASSF1A, Septin9, RNF180, SDC2, PAX1, ZNF671, BMPR1A, PLAC8, EVX1, GNB4, SIX6, PCDHGB7, DAPK1, GSTP1, HIC1, RUNX3, VHL, WT1, BMP3, NDRG4, BCAT1, Twist1, JAM3, TFPI2, CDO1, LYPD5, HOXA9, BNC1, PENK, SFRP1, PCDH8, ADAM23, CHST11, C2orf88, MCF2L, CAMK2N1, and TACSTD2.
6. The method according to claim 5, wherein the tumor-specific methylation gene target intervals are chr1:20810296-20810635, chr1:25255411-25255652, chr1:59042517-59043026, chr10:88515764-88516078, chr10:88516143-88516235, chr11:32354800-32355439, chr11:67350903-67351488, chr11:133939397-133939638, chr12:25055729-25056569, chr 12:104850537-104850822, chr13:53421948-53422217, chr13:53422689 -53422828、chr13:113623367-113623449、chr13:113623511-113623603、 chr14:60976415-60976602, chr15:83952782-83953090, chr16:58497189 -58497988、chr17:1957373-1957754、chr17:75368649-75370546、chr19: 44302727-44303241, chr19:58238546-58239068, chr2:191044925-1910 45141, chr2:207308920-207309240, chr20:21686160-21686478, chr20:2 1686644-21687729, chr3:10183433-10183998, chr3:50377764-50378580 , chr3:157821193-157821570, chr3:179168719-179168984, chr3:179169 053-179169633, chr4:81951952-81952848, chr4:84030745-84031349, ch r5:40680835-40682071, chr5:63461409-63461789, chr5:63461875-6346 2146, chr5:115151476-115152553, chr5:140797123-140797741, chr6:26 240658-26240991, chr7:19147401-19147925, chr7:27204944-27205261,<h2 style=";text-align:left;direction:ltr">chr7:27282047-27282879, chr7:27282942-27283176, chr7:93519247-93520492, chr8:41166830-41167127, chr8:41168404-41168548, chr8:57358291-57359351, chr8:97505708-97507647, chr9:90113255-90113681.
7. According to the method of claim 1, the variant gene types of the mutation site include point mutation and insertion-deletion mutation. The method according to claim 1 , wherein the methylation site comprises a site recognized by a methylation-sensitive restriction endonuclease.
9. The method according to claim 1, wherein the methylation-sensitive restriction endonuclease is selected from the group consisting of HpaI, HpaII, HhaI, AciI and combinations thereof.
10. According to the method of claim 1, the 5' end of the capture probe is a first probe binding sequence, which is complementary to the 3' end of another capture probe 1, and the 3' end of the capture probe is a second probe binding sequence, which is complementary to the 5' end of another capture probe 2; the lengths of the first and second probe binding sequences are 8-30nt, the length of the target-specific sequence is 20-80nt, and the 5' end of the capture probe is modified with biotin; the other capture probe 1 and the other capture probe 2 are not the same probe.
11. The method according to claim 1, wherein in step (3), genomic DNA is extracted from cell lines, tumor tissues or exfoliated cells, or free DNA is extracted from plasma, urine, pleural effusion or ascites.
12. The method according to claim 1, wherein the sample ligation product in step (3) includes the entire sequence of the sample DNA and the added exogenous DNA.
13. The method according to claim 11, wherein the exogenous DNA is lambda DNA, which is used to monitor the enzyme cleavage efficiency of a methylation-sensitive restriction endonuclease.
14. The method according to claim 1, wherein in step (5), 1 to 10 sample prelibraries are hybridized simultaneously.
15. The method according to claim 1, wherein the library quality inspection requires that the library concentration is greater than or equal to 1.5 ng / μL and the fragments are evenly distributed between 200 and 1000 bp.
16. A reagent for simultaneously detecting tumor-specific gene mutation and methylation in one tube, characterized in that: The reagent comprises a capture probe, which is composed of a probe binding sequence complementary to an adjacent capture probe in the same interval and a target specific sequence complementary to a tumor specific mutation gene target interval or a tumor specific methylation gene target interval.
17. The reagent according to claim 16, wherein the tumor-specific mutant gene is NRAS, CTNNB1, PIK3CA, FBXW7, APC, EGFR, BRAF, CDKN2A, PTEN, FGFR2, HRAS, KRAS, AKT1, TP53, PPP2R1A, or GNAS.
18. The reagent according to claim 17, wherein the tumor-specific mutant gene target interval is chr1:115256462-115256611, chr1:115258679-115258834, chr10:89692723-89693040, chr10:123279607-123279757, chr11:534208-534345, chr12:25378488-25378637, chr12:25380204-25380355, chr12:25398219-253983 66. chr14:105246490-105246643, chr17:7572893-7573080, chr17:7573907-7574089, chr17:7576783-7577228, chr17:7577440-7 577667, chr17:7578099-7578633, chr17:7579220-7579944, chr19:52715900-52716054, chr20:57484357-57484503, chr3:4126603 4-41266205、chr3:178916784-178916941、chr3:178921480-178921626、chr3:178936016-178936175、chr3:178951998-178952156 , chr4:153247221-153247419, chr4:153249298-153249453, chr4:153251828-153251987, chr5:112175138-112175286, chr5:11217 5578-112175730, chr7:5571691-5571899, chr7:55232932-55233170, chr7:55241573-55241776, chr7:55242374-55242553, chr7:5 5248945-55249211, chr7:55259371-55259607, chr7:55268840-55269073, chr7:140453072-140453231, chr9:21971056-21971281.
19. The agent according to claim 16, wherein the tumor-specific methylation gene is SHOX2, PTGER4, H4C6, RASSF1A, Septin9, RNF180, SDC2, PAX1, ZNF671, BMPR1A, PLAC8, EVX1, GNB4, SIX6, PCDHGB7, DAPK1, GSTP1, HIC1, RUNX3, VHL, WT1, BMP3, NDRG4, BCAT1, Twist1, JAM3, TFPI2, CDO1, LYPD5, HOXA9, BNC1, PENK, SFRP1, PCDH8, ADAM23, CHST11, C2orf88, MCF2L, CAMK2N1, and TACSTD2.
20. The reagent according to claim 19, wherein the tumor-specific methylation gene target interval is chr1:20810296-20810635, chr1:25255411-25255652, chr1:59042517-59043026, chr10:88515764-88516078, chr10:88516143-88516235, chr11:32354800-32355439, chr11:67350903-67351488, chr11:133939397-133939638, chr12:25055729-25056569, c hr12:104850537-104850822, chr13:53421948-53422217, chr13:5342268 9-53422828、chr13:113623367-113623449、chr13:113623511-113623603 , chr14:60976415-60976602, chr15:83952782-83953090, chr16:5849718 9-58497988、chr17:1957373-1957754、chr17:75368649-75370546、chr19 :44302727-44303241, chr19:58238546-58239068, chr2:191044925-1910 45141, chr2:207308920-207309240, chr20:21686160-21686478, chr20:2 1686644-21687729, chr3:10183433-10183998, chr3:50377764-50378580 , chr3:157821193-157821570, chr3:179168719-179168984, chr3:179169 053-179169633, chr4:81951952-81952848, chr4:84030745-84031349, ch r5:40680835-40682071, chr5:63461409-63461789, chr5:63461875-6346 2146, chr5:115151476-115152553, chr5:140797123-140797741, chr6:26 240658-26240991, chr7:19147401-19147925, chr7:27204944-27205261,<h2 style=";text-align:left;direction:ltr">chr7:27282047-27282879, chr7:27282942-27283176, chr7:93519247-93520492, chr8:41166830-41167127, chr8:41168404-41168548, chr8:57358291-57359351, chr8:97505708-97507647, chr9:90113255-90113681.
21. According to the reagent of claim 16, the 5' end of the capture probe is a first probe binding sequence, which is complementary to the 3' end of another capture probe 1, and the 3' end of the capture probe is a second probe binding sequence, which is complementary to the 5' end of another capture probe 2; the lengths of the first and second probe binding sequences are 8-30nt, the length of the target-specific sequence is 20-80nt, and the 5' end of the capture probe is modified with biotin; the other capture probe 1 and the other capture probe 2 are not the same probe.
22. The reagent according to claim 16, further comprising a methylation-sensitive restriction endonuclease.
23. The reagent according to claim 22, wherein the methylation-sensitive restriction endonuclease is selected from the group consisting of HpaI, HpaII, HhaI, AciI and combinations thereof.
24. Use of the reagent according to any one of claims 16 to 23 in the preparation of a diagnostic reagent for tumor mutation and methylation status.
Citation Information
Patent Citations
Capture library for detecting 50 tumor-relevant hotspot mutation genes and kit
CN106283199A
Kit for identification of gastric cancer and / or gastric polyps and application thereof
CN108977544A
Pan-cancer detection panel based on next-generation sequencing technology and application of detection panel
CN111979329A
Method for detecting methylation and mutation states of DNA sample
CN116751862A
DNA methylation level detection method and application
CN117821575A
Cited By
Biological sample treatment method, device and equipment and storage medium
CN119193846A
Construction method and kit for multi-gene multi-mutation type sequencing library for targeted therapy of lung cancer
CN119570908A
Marker combination related to benign and malignant pulmonary nodules, method for distinguishing benign and malignant pulmonary nodules and application
CN120683240A
Library construction method for detecting gastrointestinal stromal tumor molecular typing and gastrointestinal stromal tumor molecular typing method
CN121496062A
Method and kit for detecting urinary system cancer based on urine DNA methylation
CN122503505A
